Sacha Mann has been appointed a senior partner at Takeda Ventures, the corporate venture capital arm of Japan-headquartered pharmaceutical firm Takeda, according to her LinkedIn profile.
Her profile describes Mann as being in “stealth” at the unit from June 2020 to February 2021. She describes herself as a “venture capitalist with [an] interest in all modalities across oncology, neuroscience, rare disease and [gastrointestinal].”
Mann had previously been a venture partner at healthcare-focused VC firm Zoic Capital from 2018 to 2020. Inventages Venture Capital, a VC firm formed with the support of packaged food producer Nestlé, hired her as a principal in 2009 and she was promoted to venture partner in 2016 before leaving the following year.
Mann was appointed interim chief executive officer of antibody-based treatment developer Biosys UK in 2015 and CEO from 2016 to 2017. She was also a director at Phytomedics, a UK-based provider of botanical products for rheumatoid arthritis and sarcopenia, from 2013 to 2016.
Photo of Sacha Mann courtesy of LinkedIn.